CD47 and cancer: For example, reprogramming TAMs using a ZEB1 antagonist and blocking the CD47-SIRPα pathway are state-of-the-art “normalization cancer immunotherapy” strategies that can synergistically restore the antitumour properties of immune cells in the TME.